CDC and FDA work to increase availability of additional RSV vaccine for infants
The federal agencies announced the availability of additional doses of nirsevimab-alip (Beyfortus; Sanofi) for infants at high-risk of infection.
CDC and FDA work to increase availability of additional RSV vaccine for infants: © Artur - stock.adobe.com
The Centers for Disease Control and Prevention (CDC), along with the FDA, have announced the availability of more than 77,000 doses of nirsevimab-alip (Beyfortus; Sanofi), which are being immediately distrusted to hospitals and physicians through the Vaccines for Children Program, as well as through commercial channels.
Nirsevimab-alip is monoclonal antibody approved by the FDA to protect infants against severe respiratory syncytial virus (RSV).
“Helping to ensure the availability of this preventative option to reduce the impact of RSV disease on eligible babies and young children, families and the health care system remains a priority,” said Patrizia Cavazzoni, MD, director of the FDA’s Center for Drug Evaluation and Research, in a press release. “We will continue to use all our regulatory tools to help bring safe, effective and high-quality medicines to the public.”
The federal agencies said that they will continue to work closely with manufactures to maintain the availability of the vaccines through the ends of 2023 and early 2024 to meet the demand during the RSV season.
The CDC and FDA are also working with the American College of Obstetricians and Gynecologists, to encourage health care providers to use the RSV maternal vaccine. This immunization can help safeguard infants against RSV prior to birth.
Additionally, the CDC has been urging clinicians to administer the infant vaccine to patients at the highest risk of infection during this shortage period, including infants up to 6 months, as well as American Indian and Alaska Native infants.
“CDC and FDA are committed to expanding access to this important immunization so that more parents have peace of mind during the winter virus season,” said Nirav D. Shah, MD, JD, CDC’s principal deputy director.
This article was initially published by our sister publication Contemporary Pediatrics.
Reference:
CDC and FDA Expedite the Availability of Additional Doses of New RSV Immunization for Infants. CDC. November 17, 2023. Accessed November 17, 2023. https://www.cdc.gov/media/releases/2023/p1116-rsv-doses.html
Inactivated COVID-19 vaccines in pregnancy: No impact on neonatal outcome, study finds
November 28th 2023A comprehensive cohort study explored the impact of inactivated COVID-19 vaccines administered within 3 months before conception, revealing reassuring findings that neonatal outcomes, including preterm birth and NICU admission, remain unaffected.
Read More
Late-preterm antenatal corticosteroid treatment in twin pregnancies and newborn morbidity
November 27th 2023A recent retrospective cohort study found that administering antenatal corticosteroids from 34 to 36 weeks of gestation did not decrease composite neonatal respiratory morbidity in twin pregnancies, challenging conventional practices for this high-risk population.
Read More
The impact of WIC enrollment on breastfeeding rates: A comprehensive study
November 21st 2023Explore the findings of a recent study, revealing that enrollment in the Special Supplemental Nutritional Program for Women, Infants, and Children may influence breastfeeding decisions, shedding light on disparities and suggesting the need for targeted initiatives to enhance breastfeeding rates among low-income mothers.
Read More
Hematocrit levels in newborns: EPP vs. DCC study reveals surprising findings
November 7th 2023A recent study in JAMA Network Open investigates the impact of extrauterine placental perfusion versus delayed cord clamping on hematocrit levels in newborns, shedding light on potential alternatives for optimizing infant outcomes during birth.
Read More
